HomeProductsProduct SelectionsLiraglutide (GLP1)Liraglutide (GLP1) 10mg

Liraglutide (GLP1) 10mg

1 Vial $99.99 ($99.99)
Sale Most Popular!
2 Vials $199.98 $170.99
Save $28.99 ($170.99)
Sale Best Choice!
3 Vials $299.97 $243.99
Save $55.98 ($243.99)
1 Vial
2 Vials
3 Vials
4 Vials
5 Vials
10 Vials
20 Vials
40 Vials
100 Vials
Grand total

Availability: Ships today if ordered and paid by 7AM EST

Liraglutide is a derivative of GLP-1, a naturally occurring peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Liraglutide (GLP-1 Analogue) may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease.

Liraglutide has been shown to significantly decrease appetite by delaying gastric emptying and reducing intestinal motility. Liraglutide has been modified to have a longer half-life and more favorable pharmacokinetics.

Where to buy Liraglutide 10mg? Shop now for Liraglutide 10mg with exceptional quality and get more for less with our bulk sales. Quick 48-hour delivery available.


    3rd party checkout COA cust serv Purity shipping

    Liraglutide (GLP1) 10mg Properties

    Chemical Formula: C172H265N43O51
    Molecular Mass: 3751.24
    Synonyms: Liraglutide, NN2211, Liraglultidum, Liraglutidea
    PubChem: 16134956
    CAS: 204656-20-2
    Total Amount of the Active Ingredient: 10mg (1 vial)
    Shelf Life: 36 months

    Product Quality

    Lab tests are occasionally published on the website. You can have the product you bought from us tested at any HPLC licensed testing facility and if the results are negative, we will refund the following:

    Cost of HPLC test
    Total amount of the order + shipping fee

    Peer-Reviewed Studies

    From the Incretin Concept and the Discovery of GLP-1 to Today’s Diabetes Therapy

    Researchers have been looking for insulin-stimulating factors for more than 100 years, and in the 1960ties it was definitively proven that the gastrointestinal tract releases important insulinotropic factors upon oral glucose intake, so-called incretin hormones. The first significant factor identified was the duodenal glucose-dependent insulinotropic polypeptide, GIP, which however, turned out not to stimulate insulin secretion in patients with type 2 diabetes. But resection experiments clearly indicated the presence of an additional incretin, and in 1986, an unexpected processing fragment of the recently identified glucagon precursor, proglucagon, namely truncated glucagon-like peptide 1 (GLP-1 7-36 amide), was isolated from the gut and found to both stimulate insulin secretion and inhibit glucagon secretion. The peptide also inhibited appetite and food intake. Unlike GIP, this peptide had preserved effects in patients with type 2 diabetes and it was soon documented to have powerful antidiabetic effects in clinical studies. Its utility was limited, however, because of an extremely short half-life in humans, but this problem had two solutions, both of which gave rise to important antidiabetic drugs: (1) orally active inhibitors of the enzyme dipeptidylpeptidase 4 (DPP-4 inhibitors), which was responsible for the rapid degradation; the inhibitors protect endogenous GLP-1 from degradation and thereby unfold its antidiabetic activity, and (2) long-acting injectable analogs of GLP-1 protected against DPP-4 degradation. Particularly, the latter, the GLP-1 receptor agonists, either alone or in various combinations, are so powerful that treatment allows more than 2/3 of type 2 diabetes patients to reach glycemic targets. In addition, these agents cause a weight loss which, with the most successful compounds, may exceed 10% of body weight. Most recently they have also been shown to be renoprotective and reduce cardiovascular risk and mortality.

    Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update

    Angiotensin II (Ang II), a peptide hormone generated as part of the renin-angiotensin system, has been implicated in the pathophysiology of many cardiovascular diseases such as peripheral artery disease, heart failure, hypertension, coronary artery disease and other conditions. Liraglutide, known as an incretin mimetic, is one of the glucagon-like peptide-1 (GLP-1) receptor agonists, and has been proven to be effective in the treatment of cardiovascular disorders beyond adequate glycemic control. The objective of this review is to compile our recent experimental outcomes-based studies, and provide an overview the cardiovascular protection from liraglutide against Ang II- and pressure overload-mediated deleterious effects on the heart. In particular, the mechanisms of action underlying the inhibition of oxidative stress, vascular endothelial dysfunction, hypertension, cardiac fibrosis, left ventricular hypertrophy and heart failure with liraglutide are addressed. Thus, we support the notion that liraglutide continues to be a useful add-on therapy for the management of cardiovascular diseases.

    A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

    Background: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity.

    Methods: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56.

    Results: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment.

    Conclusions: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).




    If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.


    The information provided above is not intended to substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider. In no case should medical advice be disregarded or delayed because of what you have read or seen. We bear no responsibility or liability for your use of any of our research compounds and products. Please note that they are being sold for research purposes ONLY. We do NOT condone any personal use.

    Note: In some cases wherein the assigned top colors are out of stock, a different top color will be used to ensure that your order will not be delayed. Should you need assistance identifying the peptide vial that you received, please send us an email at [email protected].


    The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: “in glass”) are performed outside the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat and/or cure any medical condition, ailment or disease. Bodily introduction of any kind into animals or human is strictly prohibited by law.

    How Many Vials?

    1 Vial, 2 Vials, 3 Vials, 4 Vials, 5 Vials, 10 Vials, 20 Vials, 40 Vials, 100 Vials


    Liraglutide (GLP1) 10mg Vials  

    How to reconstitute Liraglutide (GLP1) 10mg vials?

    Liraglutide (GLP1) 10mg vials contain a peptide powder, which is typically a puck or loose bits due to shipping. To reconstitute a Liraglutide (GLP1) 10mg vials, researchers typically use bacteriostatic water, combining it with the peptide powder according to the specific requirements of their research protocols.


    How to dose Liraglutide (GLP1) 10mg?

    The dosing of Liraglutide (GLP1) 10mg in vials form will vary according to the experiment being conducted. We do not provide dosage recommendations as our products are intended for research purposes only.


    How to administer Liraglutide (GLP1) 10mg?

    There are multiple methods of administering research products that are under investigation in various studies. The choice of administration technique should align with the specific goals and design of the researcher’s study. We provide products solely for research use, we do not offer advice on administration methods.